Growth Factors

The Increasing Global Prevalence of Infectious and Chronic Diseases

The rising load of infectious and chronic conditions in the global setting is one of the factors driving the mRNA therapeutics market. According to the statistics posted by the World Health Organization (WHO), every year about 17 million deaths are caused by infectious diseases. Conversely, chronic diseases that include cancer, heart diseases, as well as diabetes are the major causes of death in the world with approximately 74 percent of the world mortalities attributed to these diseases. The COVID-19 crisis has also offered up potential of the hybrid mRNA technology in the creation of vaccines in a shorter span of time; hence, there will be other applications of the technology in developing other infectious diseases like influenza, Zika, as well as HIV. In addition, the increase in the rate of cancer that is projected to reach 28.4 million new cases by 2040 is also fuelling research activities on the development of property-based cancer immunotherapies and thus it is boosting the market.

Restrainting Factors

Rising Manufacturing Expenses

It has escalating manufacturing costs and it is a major restraint to the market of mRNA therapeutics globally. Complex steps involved in the production of mRNA-based drugs entail nucleic acid production, production of lipid nanoparticles and purpose techniques which are highly technical demanding high precision instruments. Also, the expenses of maintaining the storage and transportation cold are additional. The cost of raw materials and managerial employees besides the regulatory requirement further increments total amount of investment which is imperative. These huge spending could limit the access of smaller biotech firms into the market. They can serve as a bottleneck on mass commercialization especially on developing regions of the world and thus, affect the affordability and accessibility of such mRNA-based therapy to patients in every corner of the globe.

By Product

Vaccines to Occupy Major Share of 35.00% in the Market during the Forecast Period

The vaccines segment represented the largest portion of the mRNA therapeutics market, and it will stay in the leading position since the effectiveness and speed of the development can be demonstrated. The effectiveness of the mRNA-based COVID-19 vaccine platform, both the Pfizer-Biotech Comirnaty vaccine and Modern Spikevax has shown in the recent past the potential of the platform to yield high effectiveness and safety within unequalled timelines. Besides COVID-19, mRNA vaccines are under development against seasonal influenza, respiratory syncytial virus (RSV), Zika virus and various cancers, and are increasingly entering the market. Good government funding, global vaccination as well as increase in the levels of investment by the private sector has accelerated vaccine research/ commercialization. On the contrary, the mRNA-based drugs are still under the earlier clinical trials, which does not bode well with respect to their market impact when compared to the distribution of the vaccines and the tested regulation techniques.

By Application

Infectious Diseases to Occupy Major Share of 31.22% in the Market during the Forecast Period

It is characterized by its superiority where mRNA therapies recently gained acceptance in their use in treating infectious diseases today.  At present, the mRNA-based vaccines are approved against COVID-19 and respiratory syncytial virus (RSV) strengthening the position of that segment.  But the oncology market is anticipated to grow considerably within the upcoming years since the mRNA technology gains popularity in the treatment of cancer.  Major biopharmaceutical enterprises are putting a lot of resources on this area. As an example, in August 2024, BioNTech initiated global clinical testing of an mRNA-based vaccine candidate, BNT116, intended to treat non-small cell lung cancer (NSCLC), showing that mRNA is increasingly being deployed in the area of non-small cell lung cancer treatment.

By Geography

North America Region to Occupy Major Share of 33.00% in the Market during the Forecast Period

North America rules the market since the strength in the region is the financing of the research, federal effort, and the number of clinical trials being conducted. It possesses a highly advanced health system that has massive investment in R&D both in the government and privately. The United States dominates its North American market because in the region there are global reputed drug companies and biotechnology companies, the environment is favourable in terms of rules and regulation, and the rate of adopting new therapies is high. Moreover, numerous vaccine and drug approvals in the U.S. stimulate the development of the market. To give an example, in May 2024, United States Federal statistics allowed mesial mRNA respiratory syncytial virus mRNA (RSV) vaccine, developed by Modern Inc., to enter the market in the United States, thereby being a major step toward effective prevention of infectious diseases and a new boost to the segment of the most progressive biopharmaceutical development.

List Of Top Players

• Moderna Inc.
• BioNTech SE
• CureVac N.V.
• ARCTURUS THERAPEUTICS
• Sanofi
• GSK Plc.
• Argos Therapeutics Inc.
• Ethris
• Pfizer Inc.
• AstraZeneca
• Crispr Therapeutics
• Sangamo Therapeutics, Inc.

Key Industry Developments

• In January 2023, Biotech SE has entered into a strategic alliance with the UK government to deliver personalized messenger RNA (mRNA) cancer therapies to as many as 10,000 patients by 2030, and contribute to revenues.
• In August 2023 CureVac initiated dosing the first patient in a Phase 2 trial of modified COVID-19 mRNA vaccine candidates, in collaboration with GSK Plc.
• Modern Inc. will use mRNA research to develop cancer, respiratory and rare diseases this month (August 2023), and this will enhance the revenue.

Table Of Contents

1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. MARKET INTRODUCTION
   2. MARKET DRIVERS
   3. MARKET RESTRAINTS
   4. FUTURE OPPORTUNITIES
   5. MARKET TRENDS
   6. PORTER’S FIVE FORCES ANALYSIS
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Suppliers
      4. Bargaining Power of Buyers
      5. Intensity of Competitive Rivalry
   7. VALUE CHAIN & PROFIT MARGIN ANALYSIS
   8. PRICING ANALYSIS
   9. REGULATORY FRAMEWORK
   10. COVID-19 IMPACT ANALYSIS
   11. PRODUCT LIFE CYCLE ANALYSIS
   12. PESTLE ANALYSIS
   13. MICRO ECONOMIC ANALYSIS
   14. Market Hospitals & Clinics Insights (Enterprise license)
       • Consumer Analysis (List of Potential Consumers)
       • Top 10 Country-Wise Import & Export Data (If Applicable)
       • Regulatory Bodies & Authorization Across the Globe
       • Key Conferences & Events: Next Two Years
       • Top Patents for The Market
5. GLOBAL MRNA THERAPEUTICS MARKET REVENUE & SHARE ANALYSIS (2023-2032)
   1. By Product
      1. Vaccines      
      2. Drugs
   2. By Application 
      1. Infectious Diseases
      2. Oncology
      3. Respiratory Diseases
      4. Others
   3. By Indication
      1. Hospitals & Clinics
      2. Research Organizations
      3. Others
6. GLOBAL MRNA THERAPEUTICS MARKET REVENUE & SHARE ANALYSIS (2023-2032), BY REGION
   1. NORTH AMERICA 
      1. U.S.
      2. Canada
      3. Mexico
   2. EUROPE
      1. Germany
      2. UK
      3. France
      4. Italy
      5. Spain
      6. Rest of Europe
   3. ASIA PACIFIC 
      1. China
      2. Japan
      3. India
      4. South Korea
      5. Rest of APAC
   4. MIDDLE EAST & AFRICA
      1. GCC
      2. South Africa
      3. Rest of MEA
   5. LATIN AMERICA
      1. Brazil
      2. Argentina
      3. Rest of LATAM

For all the segments and sub-segments, Qualitative as well as Quantitative data will be provided. In Quantitative we provide the historic (2023), base (2024), estimated (2025) and forecasted (2025-2032) market value in USD Million, Share in % with a CAGR (2025-2032). This data would be provided on a regional as well as country level.

1. COMPETITIVE LANDSCAPE
   1. OVERVIEW
   2. KEY PLAYERS MARKET SHARE ANALYSIS
   3. LIST OF KEY STRATEGIC DEVELOPMENTS 
2. COMPANY PROFILES
   1. MODERNA INC.
      1. Company Overview
      2. Company Financial Insights (Total Revenue, Revenue By Business Segments, and By Region)
      3. Product Benchmarking
      4. Key Strategic Developments (Merges & Acquisitions, Partnership /Agreements/Joint Venture, Expansion, New Product Launches, and other developments)
      5. Business Strategic Overview
      6. SWOT Analysis
   2. BIONTECH SE
   3. CureVac N.V.
   4. ARCTURUS THERAPEUTICS
   5. SANOFI
   6. GSK PLC.
   7. ARGOS THERAPEUTICS INC.
   8. ETHRIS
   9. PFIZER INC.
   10. ASTRAZENECA
   11. CRISPR THERAPEUTICS
   12. SANGAMO THERAPEUTICS, INC. 
3. LIST OF SOURCES

DISCLAIMER